Louise Jones

Louise Jones

Auto-generated profile, based on publicly available information

Louise Jones

Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2017 in Journal of Medical Internet Research
Verified
Journal Article
Open access
AFAndrew Farmer
Andrew Farmer
VWVeronika Williams
Veronika Williams
CVCarmelo Velardo
Carmelo Velardo
SSSyed Ahmar Shah
Syed Ahmar Shah
LYLy-Mee Yu
Ly-Mee Yu
LTLionel Tarassenko
Lionel Tarassenko
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

21 March 2008 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
NMNeelika Malavige
Neelika Malavige
LJL. Jones
L. Jones
ABAnthony Black
Anthony Black
GOG. S. Ogg
G. S. Ogg
Varicella zoster viru (VZV)-specific T cell responses are believed to be vital in recovery from primary VZV infection and also in the prevention of viral reactivation. While glycoprotein E (gE) is the most abundant and one of the most immunogenic proteins of the virus, there are no data addressing potential T cell epitopes within gE, nor the phenotype of specific T cells. Using interferon gamma enzyme-linked immunospot assays and intracellular cytokine assays, we identified gE-specific immune responses in 20 adult healthy immune donors which were found to be dominated by the CD4+ subset of T cells. We characterized three immune dominant epitopes within gE restricted through DRB1*1501, DRB1*07 and DRB4*01, and used DRB1*1501 class II tetrameric complexes to determine the ex vivo frequency and phenotype of specific T cells. In healthy immune donors, the cells were largely positive for CCR7, CD28 and CD27, but expressed variable CD62L and low levels of cutaneous lymphocyte associated antigen with evidence of recent activation. In summary, we show that circulating gE-specific CD4+ T cells are detected at a relatively high frequency in healthy immune donors and show evidence of recent activation and mixed central and effector memory phenotype. These data would be compatible with frequent exposure to replicative cycle antigens in healthy donors and are consistent with a role for gE-specific CD4+ T cells in the control of viral replication.

21 February 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
AFAndrew Farmer
Andrew Farmer
LJLouise Jones
Louise Jones
NNNikki Newhouse
Nikki Newhouse
CKCassandra Kenning
Cassandra Kenning
NWNicola Williams
Nicola Williams
DFDavid P French
David P French
Background: Type 2 diabetes is a common lifelong condition that affects over 400 million people worldwide. The use of effective medications and active self-management can reduce the risk of serious complications. However, people often have concerns when starting new medications and face difficulties in taking their medications regularly. Support provided by brief messages delivered through mobile phone–based SMS text messages can be effective in some long-term conditions. We have identified promising behavior change techniques (BCTs) to promote medication adherence in this population via a systematic review and developed SMS text messages that target these BCTs. Feasibility work has shown that these messages have fidelity to intended BCTs, are acceptable to patients, and are successful in changing the intended determinants of medication adherence. We now plan to test this intervention on a larger scale in a clinical trial. Objective: The aim of this trial is to determine the effectiveness and cost-effectiveness of this intervention for reducing cardiovascular risk in people with type 2 diabetes by comparing it with usual care. Methods: The trial will be a 12-month, multicenter, individually randomized controlled trial in primary care and will recruit adults (aged ≥35 years) with type 2 diabetes in England. Consenting participants will be randomized to receive short SMS text messages intended to affect a change in medication adherence 3 to 4 times per week in addition to usual care. The aim is to test the effectiveness and cost-effectiveness of the intervention when it is added to usual care. The primary clinical outcome will be a composite cardiovascular risk measure. Data including patient-reported measures will be collected at baseline, at 13 and 26 weeks, and at the end of the 12-month follow-up period. With 958 participants (479 in each group), the trial is powered at 92.5% to detect a 4–percentage point difference in cardiovascular risk. The analysis will follow a prespecified plan. A nested quantitative and qualitative process analysis will be used to examine the putative mechanisms of behavior change and wider contextual influences. A health economic analysis will be used to assess the cost-effectiveness of the intervention. Results: The trial has completed the recruitment phase and is in the follow-up phase. The publication of results is anticipated in 2024. Conclusions: This trial will provide evidence regarding the effectiveness and cost-effectiveness of this intervention for people with type 2 diabetes. Trial Registration: ISRCTN Registry ISRCTN15952379; https://www.isrctn.com/ISRCTN15952379 International Registered Report Identifier (IRRID): DERR1-10.2196/32918

1 March 2025 in Health Technology Assessment
Verified
Journal Article
Open access
PDF file
FHF D Richard Hobbs
F D Richard Hobbs
RMRichard J McManus
Richard J McManus
CTClare J Taylor
Clare J Taylor
NJNicholas Jones
Nicholas Jones
JRJoy Rahman
Joy Rahman
LYLy-Mee Yu
Ly-Mee Yu
Background: Chronic kidney disease affects around 10% of the global population and is associated with significant risk of progression to end-stage renal disease and vascular events. Aldosterone receptor antagonists such as spironolactone have shown prognostic benefits in patients with heart failure, but effects on patients with chronic kidney disease are uncertain. Objectives: To determine the effect of low-dose spironolactone on mortality and cardiovascular outcomes in people with chronic kidney disease stage 3b. Design: Prospective randomised open blinded end-point trial. Settings: Three hundred and twenty-nine general practitioner practices throughout the United Kingdom. Participants: Patients meeting the criteria for chronic kidney disease stage 3b (estimated glomerular filtration rate 30–44 ml/minute/1.73 m2) according to National Institute for Health and Care Excellence guidelines were recruited. Due to the higher than anticipated measurement error/fluctuations, the eligible range was extended to 30–50 ml/minute/1.73 m2 following the initial recruitment period. Intervention: Participants were randomised 1 : 1 to receive either spironolactone 25 mg once daily in addition to standard care, or standard care only. Outcome measures: Primary outcome was the first occurring of all-cause mortality, first hospitalisation for heart disease (coronary heart disease, arrhythmia, atrial fibrillation, sudden death, failed sudden death), stroke, heart failure, transient ischaemic attack or peripheral arterial disease, or first occurrence of any condition not listed at baseline. Secondary outcome measures included changes in blood pressure, renal function, B-type natriuretic peptide, incidence of hyperkalaemia and treatment costs and benefits. Results: One thousand four hundred and thirty-four participants were randomised of the 3022 planned. We found no evidence of differences between the intervention and control groups in terms of effectiveness with the primary combined vascular end points, nor with the secondary clinical outcomes, including progression in renal decline. These results were similar for the total treatment periods or a 3-year follow-up period as originally planned. More adverse events were experienced and more participants discontinued treatment in the intervention group. Two-thirds of participants randomised to spironolactone stopped treatment within six months because they met pre-specified safety stop criteria. The addition of low-dose spironolactone was estimated to have a cost per quality-adjusted life-year gained value above the National Institute for Health and Care Excellence’s threshold of £30,000. Limitations: Main limitations were difficulties in recruiting eligible participants resulting in an underpowered trial with poor ethnic diversity taking twice as long as planned to complete. We have explored the data in secondary analyses that indicate that, despite these difficulties, the findings were reliable. Conclusions: The benefits of aldosterone receptor antagonism in chronic kidney disease trial found no evidence to support adding low-dose spironolactone (25 mg daily) in patients with chronic kidney disease stage 3b: there were no changes to cardiovascular events during the trial follow-up, either for the combined primary or individual components. There was also no evidence of benefit observed in rates of renal function decline over the trial, but much higher initial creatinine rise and estimated glomerular filtration rate decline, and to a higher percentage rate, in the intervention arm in the first few weeks of spironolactone treatment, which resulted in a high proportion of participants discontinuing spironolactone treatment at an early stage. These higher rates of negative renal change reduced in scale over the study but did not equalise between arms. The addition of 25 mg of spironolactone therefore provided no reno- or cardio-protection and was associated with an increase in adverse events. Future work: These findings might not be applicable to different mineralocorticoid receptor antagonists. Study registration: Current Controlled Trials ISRCTN44522369. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 12/01/52) and is published in full in Health Technology Assessment; Vol. 29, No. 5. See the NIHR Funding and Awards website for further award information.

1 August 2010 in Journal of Infection
Verified
Journal Article
Closed access
PDF file
NMNeelika Malavige
Neelika Malavige
LJLouise Jones
Louise Jones
SKS.D. Kamaladasa
S.D. Kamaladasa
AWAnanda Wijewickrama
Ananda Wijewickrama
SSSuranjith L Seneviratne
Suranjith L Seneviratne
GOGraham S. Ogg
Graham S. Ogg

1 October 2006 in Journal of Immunological Methods
Verified
Journal Article
Closed access
ABAnthony Black
Anthony Black
LJLouise Jones
Louise Jones
MAMichael Ardern-Jones
Michael Ardern-Jones
GOGraham S. Ogg
Graham S. Ogg